Related content

A phase I clinical trial of low-dose interferon-α-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma

By Amato Robert   Khan Muhammad  

Cancer Chemotherapy and Pharmacology, Vol. 61, Iss. 6, 2008-05 ,pp. : 1069-1073

Springer Publishing Company

Access to resources Recommend Favorite

A Phase II Trial of Recombinant Interferon Alpha-2b and Cisplatin in Metastatic Melanoma

By Baekke Janne   Rytter Carsten   Mouridsen Henning   Madsen Ebbe Lindegård   Møholt Kirsten   Bastholt Lars  

Acta Oncologica, Vol. 39, Iss. 5, 2000-10 ,pp. : 625-628

Informa Healthcare

Access to resources Recommend Favorite

TNF-Based Isolated Limb Perfusion Followed by Consolidation Biotherapy with Systemic Low-dose Interferon Alpha 2b in Patients with In-transit Melanoma Metastases: A Pilot Trial

By Rossi Carlo  

Annals of Surgical Oncology, Vol. 15, Iss. 4, 2008-04 ,pp. : 1218-1223

Springer Publishing Company

Access to resources Recommend Favorite

Metastatic renal cell carcinoma treated with Peg-interferon alfa-2b

By Lyrdal David   Stierner Ulrika   Lundstam Sven  

Acta Oncologica, Vol. 48, Iss. 6, 2009-08 ,pp. : 901-908

Informa Healthcare

Access to resources Recommend Favorite

A Phase II Study of Dacarbazine, Cisplatin, Interferon- and High-dose Interleukin-2 in 'Poor-risk' Metastatic Melanoma

By Proebstle T.M.   Scheibenbogen C.   Sterry W.   Keilholz U.  

European Journal of Cancer, Vol. 32, Iss. 9, 1996-08 ,pp. : 1530-1533

Elsevier

Access to resources Recommend Favorite